Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Electrical Stimulation for the Treatment of Glaucoma
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Eligibility
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and
complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the
following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2
testing. Reliable visual field measures, fixation losses do not exceed 20% and false
positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically
stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by
mean deviation. If both eyes qualify and have the same MD, the patient may choose
which eye they are willing to enter, or else a randomization procedure will assign one
eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision
is impaired to the point where he/she cannot read the informed consent document, the
document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited
to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated
in any other clinical trial of a drug by ocular (if in the study eye) or systemic
administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition
that would increase the risk of participation in the study or may interfere with the
study procedures, evaluations and outcome assessments. Including but not limited to
all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as
clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not
MRI-compatible. Note: metallic dental implants and titanium screws or plates are
acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not
willing to complete the schedule of events (SOE) and/or unable to confirm follow-up
participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting